GrowingWithAK
← Back

Tata Mutual Fund · #152564

Tata Nifty MidSmall Healthcare Index Fund - Direct Plan - Growth Option

Other · Index Funds · Direct · Growth

Direct TER: 0.58% · as of

5-year NAV · change the window using the controls in the rolling-returns card below ↓

2024-04-30 → 2026-10-22

min ₹9.80 change +40.4% max ₹15.62

Latest NAV

₹14.1577

as of 2026-10-22 · -0.37% vs 2026-10-21

Earliest NAV in archive

2024-04-30

AMFI archive begins Apr 2006

Worst peak-to-trough drawdown

-17.54%

trough 2025-02-28 (since archive start)

Trailing CAGR vs assigned benchmark

Window Scheme CAGR Benchmark CAGR Excess Period
1y +8.54% — — 2025-10-23 → today · 1.0y

Benchmark assignment is mapped by category and sub-category from public sources. "Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).

Rolling 1-year returns distribution · 366 daily entry points · last 5 years

Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.

0% -2.0% to -1.1%: 5 windows -1.1% to -0.2%: 13 windows -0.2% to +0.7%: 9 windows +0.7% to +1.7%: 6 windows +1.7% to +2.6%: 12 windows +2.6% to +3.5%: 13 windows +3.5% to +4.5%: 16 windows +4.5% to +5.4%: 20 windows +5.4% to +6.3%: 13 windows +6.3% to +7.3%: 12 windows +7.3% to +8.2%: 6 windows +8.2% to +9.1%: 13 windows +9.1% to +10.0%: 7 windows +10.0% to +11.0%: 9 windows +11.0% to +11.9%: 13 windows +11.9% to +12.8%: 16 windows +12.8% to +13.8%: 17 windows +13.8% to +14.7%: 19 windows +14.7% to +15.6%: 19 windows +15.6% to +16.5%: 22 windows +16.5% to +17.5%: 21 windows +17.5% to +18.4%: 10 windows +18.4% to +19.3%: 18 windows +19.3% to +20.3%: 19 windows +20.3% to +21.2%: 20 windows +21.2% to +22.1%: 12 windows +22.1% to +23.0%: 4 windows +23.0% to +24.0%: 1 windows +24.0% to +24.9%: 0 windows +24.9% to +25.8%: 0 windows -2% +26%

Median 1y return

+12.7%

Mean 1y return

+11.6%

Best / worst 1y

+25.8% / -2.0%

Windows positive

95%

5th %ile -0.0%
25th %ile +5.2%
75th %ile +16.8%
95th %ile +21.2%

Beat-benchmark consistency · vs assigned benchmark, across overlapping windows

Of all the rolling windows we observed, how often did this fund's return exceed the benchmark's over the same window. A higher fraction means more consistent outperformance, but says nothing about future windows.

Period Windows beat Total windows % beat Avg excess
(annualised)
1y rolling 3 366 1% -0.3%

Monthly returns · since inception (Apr 2024)

How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.

Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year
2026 -4.9 +5.4 -5.2 +7.8 +6.2 +4.9 +3.2 +1.6 -3.0 -5.4 · · +9.8
2025 -9.0 -7.7 +10.1 -0.2 +1.0 +5.3 +4.3 -4.2 -0.5 +2.1 +0.3 -0.9 -0.9
2024 · · · · -2.2 +6.7 +8.5 +7.2 +1.8 +1.1 -1.6 +4.9 +29.1
Avg -7.0 -1.1 +2.4 +3.8 +1.7 +5.7 +5.3 +1.5 -0.6 +1.6 -0.6 +2.0 -0.9

All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row. The Avg row is the plain average of each column across the years shown (1 complete calendar year in the last column); the running month is left out of it.

Portfolio mix · asset class breakdown as of 2026-09-30

Equity 100.1%
Equity split: Mid 67.9% Small 32.2%

Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings

Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).

  • Mid Cap 67.8%
  • Small Cap 32.2%

Index overlap

· vs · share of this fund's AUM that sits in stocks the index also includes

No holdings data yet for this fund.

Top stocks held · 30 holdings as of 2026-09-30 See changes vs previous snapshot →

Stock Sector % of fund
LAURUS LABS LTD Pharmaceuticals & Biotechnology 11.84%
LUPIN LTD Pharmaceuticals & Biotechnology 7.57%
AUROBINDO PHARMA LTD Pharmaceuticals & Biotechnology 7.09%
FORTIS HEALTHCARE LTD Healthcare Services 6.16%
GLENMARK PHARMACEUTICALS LTD Pharmaceuticals & Biotechnology 5.40%
ALKEM LABORATORIES LTD Pharmaceuticals & Biotechnology 4.78%
MANKIND PHARMA LTD Pharmaceuticals & Biotechnology 4.36%
IPCA LABORATORIES LTD Pharmaceuticals & Biotechnology 4.11%
BIOCON LTD Pharmaceuticals & Biotechnology 3.96%
GLAND PHARMA LTD Pharmaceuticals & Biotechnology 3.55%
SAI LIFE SCIENCES LTD Pharmaceuticals & Biotechnology 3.24%
KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD Healthcare Services 3.06%
ASTER DM QUALITY CARE LTD Healthcare Services 2.86%
NEULAND LABORATORIES LTD Pharmaceuticals & Biotechnology 2.83%
WOCKHARDT LTD Pharmaceuticals & Biotechnology 2.68%
ACUTAAS CHEMICALS LTD Pharmaceuticals & Biotechnology 2.61%
AJANTA PHARMA LTD Pharmaceuticals & Biotechnology 2.53%
DR. LAL PATH LABS LTD Healthcare Services 2.38%
ABBOTT INDIA LTD Pharmaceuticals & Biotechnology 2.17%
PIRAMAL PHARMA LTD Pharmaceuticals & Biotechnology 1.97%

Sector mix

Healthcare: 100.0%
  • Healthcare 100.0%

Risk metrics, trailing 3y (609 matched daily returns, 2024-05-02 → 2026-10-22)

Sharpe

+0.59

excess return per unit of total volatility

Sortino

+0.81

excess return per unit of downside vol

Calmar

—

CAGR / |max DD| in window

Beta vs benchmark

+1.00

scheme sensitivity to benchmark moves

Tracking error

+0.45%

annualised stdev of (scheme − benchmark)

Up capture

+99.7%

% of benchmark gain captured on up days

Down capture

+99.5%

% of benchmark loss participated in

Risk-free rate assumed 6.0% annualised. Benchmark = Nifty MidSmall Healthcare (assigned by category mapping).

Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.